Clinical Practice Study Open Access
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Dec 27, 2017; 9(12): 270-280
Published online Dec 27, 2017. doi: 10.4240/wjgs.v9.i12.270
Risk factors for pancreatic fistula following pancreaticoduodenectomy: A retrospective study in a Thai tertiary center
Narongsak Rungsakulkij, Somkit Mingphruedhi, Pongsatorn Tangtawee, Chonlada Krutsri, Paramin Muangkaew, Wikran Suragul, Suraida Aeesoa, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
Penampai Tannaphai, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
ORCID number: Narongsak Rungsakulkij (0000-0003-3522-5800); Somkit Mingphruedhi (0000-0002-1404-1968); Pongsatorn Tangtawee (0000-0001-9598-5479); Chonlada Krutsri (0000-0001-6418-6578); Paramin Muangkaew (0000-0002-2470-8164); Wikran Suragul (0000-0002-9933-9279); Penampai Tannaphai (0000-0002-1873-1771); Suraida Aeesoa (0000-0002-4137-3861).
Author contributions: Rungsakulkij N contributed to design of the work, data collection, interpretation of data, writing and drafting the work; Mingphruedhi S, Tangtawee P and Krutsri C contributed to data collection and analysis; Muangkaew P, Suragul W and Tannapai P contributed to data collection; Aeesoa S contributed to data analysis.
Institutional review board statement: The study was reviewed and approved by the Ramathibodi Hospital Institutional Review Board Committee on Human Rights Related to Research Involving Human Subjects. The protocol number is ID 12-59-50.
Informed consent statement: Not applicable.
Conflict-of-interest statement: All authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Narongsak Rungsakulkij, MD, FRCS (Gen Surg), Lecturer, Surgeon, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ramathibodi Hospital, 270 Praram VI road, Ratchathewi, Bangkok 10400, Thailand. narongsak.run@mahidol.ac.th
Telephone: +66-2-2011527 Fax: +66-2-2012471
Received: July 24, 2017
Peer-review started: July 26, 2017
First decision: September 11, 2017
Revised: September 15, 2017
Accepted: October 30, 2017
Article in press: October 30, 2017
Published online: December 27, 2017

Abstract
AIM

To analyze the risk factors of postoperative pancreatic fistula following pancreaticoduodenectomy in a Thai tertiary care center.

METHODS

We retrospectively analyzed 179 patients who underwent pancreaticoduodenectomy at our hospital from January 2001 to December 2016. Pancreatic fistula were classified into three categories according to a definition made by an International Study Group on Pancreatic Fistula. The risk factors for pancreatic fistula were analyzed by univariate analysis and multivariate logistic regression analysis.

RESULTS

Pancreatic fistula were detected in 88/179 patients (49%) who underwent pancreaticoduodenectomy. Fifty-eight pancreatic fistula (65.9%) were grade A, 22 cases (25.0%) were grade B and eight cases (9.1%) were grade C. Clinically relevant pancreatic fistula were detected in 30/179 patients (16.7%). The 30-d mortality rate was 1.67% (3/179 patients). Multivariate logistic regression analysis revealed that soft pancreatic texture (odds ratio = 3.598, 95%CI: 1.77-7.32) was the most significant risk factor for pancreatic fistula. A preoperative serum bilirubin level of > 3 mg/dL was the most significant risk factor for clinically relevant pancreatic fistula according to univariate and multivariate analysis.

CONCLUSION

Soft pancreatic tissue is the most significant risk factor for postoperative pancreatic fistula. A high preoperative serum bilirubin level (> 3 mg/dL) is the most significant risk factor for clinically relevant pancreatic fistula.

Key Words: Risk factors, Pancreatic fistula, Pancreas, Pancreatectomy, Pancreaticoduodenectomy

Core tip: Pancreaticoduodenectomy is a high morbidity operation. The most common perioperative complication is postoperative pancreatic fistula. We retrospectively analyzed 179 patients who underwent pancreaticoduodenectomy at our hospital. We found that soft pancreatic tissue is the most significant risk factor for postoperative pancreatic fistula. A high preoperative serum bilirubin level (> 3 mg/dL) is the most significant risk factor for clinically relevant pancreatic fistula.



INTRODUCTION

Pancreaticoduodenectomy (PD) is the standard treatment for resectable periampullary and pancreatic tumors. PD is an example of major surgery and is a complicated operation to perform for the general surgeon. Current mortality rates are low; previous reports have suggested a perioperative mortality rate of less than 5%[1-3]. However, high morbidity rates have also been reported, some reaching up to 50%[3-7]. The most common complication following PD is postoperative pancreatic fistula (POPF). POPF is the major cause of complications such as delayed gastric emptying (DGE), postoperative hemorrhage, intra-abdominal infection and increased length of hospital stay (LOH)[8].

Many risk factors have been reported for POPF, including obesity, soft pancreatic texture, small pancreatic duct and low volume center[9-15]. Some studies have investigated ways to improve the surgical outcome and reduce POPF, including the placement of an external and internal trans-anastomotic pancreatic duct[16,17], pancreatogastrostomy[18-20], omental roll-up around pancreaticoenteric (PE) anastomosis[21], application of fibrin sealants around PE anastomosis[22,23] and prophylaxis with somatostatin analogs[24-25]. However, the outcomes of these different methods remain controversial.

Recently, a soft pancreas and high body mass index (BMI) were reported as the most common risk factors for POPF[9-13]. However, POPF risk factors have not been studied in a Thai population before. The aim of this study was to analyze the risk factors of POPF following PD in a Thai tertiary care center.

MATERIALS AND METHODS
Patients

From January 2001 to December 2016, 210 consecutive patients underwent PD at the Department of Surgery in Ramathibodi Hospital, Bangkok, Thailand and were considered for inclusion in the study. Patients who underwent a concomitant hepatic resection were excluded; in the end, a total of 179 patients were included. Patient data were retrospectively reviewed. These included age, gender, weight, BMI, underlying disease, serum albumin, preoperative total bilirubin levels and preoperative biliary drainage (PBD). In addition, we recorded the use of percutaneous trans-hepatic biliary drainage or placement of an endoscopic internal biliary stent. We also reviewed the type of operation, pancreatic texture, pancreatic duct size, type of PE anastomosis, use of trans-anastomotic pancreatic duct stent, pathological diagnosis, operative time and operative blood loss. Ethical permission for this study was obtained from the hospital’s ethics committee.

Preoperative evaluation

The general condition of patients and any co-morbid conditions were preoperatively assessed by a physician, surgeon and internist. The diagnosis and clinical staging of the disease were reviewed preoperatively by a multidisciplinary team including surgeons, radiologists and gastroenterologists.

Operative approach

Routine antibiotic prophylaxis was administered 30 min before the incision. PD is classified into classical PD and pylorus-preserved PD (PPPD) and the type of surgery depended on the surgeon’s own preference. Reconstruction after resection was performed using Child’s technique, starting with a pancreaticojejunostomy (PJ). A PJ can be performed using either a invagination or duct to mucosa technique and this was decided based on the surgeon’s preference. A trans-anastomotic pancreatic duct stent was placed in selected patients, depending on surgeon’s preference. The trans-anastomotic pancreatic duct stent was either internal (in the jejunum) or external (partly outside the body). After PJ, biliary-enteric anastomosis was performed followed by a gastro-jejunostomy or duodeno-jejunostomy. A Braun loop jejunojejunostomy was performed in some patients, according to the surgeon’s preference. Pancreatic texture was classified into hard, firm or soft consistency based on palpitation by the surgeon. A closed peri-anastomotic drainage system was placed routinely.

Postoperative complications

After surgery, patients were transferred to a critical care unit or intermediate ward. Routine biochemical analyses of patients’ blood were performed. An oral diet was started as soon as the output gastric content was < 400 mL and a positive bowel movement occurred. Parenteral nutrition was initiated if the patients did not have a bowel movement or the gastric content was > 400 mL after postoperative day (POD) 3.

POPF was defined according to International Study Group of Pancreatic Fistula (ISGPF) guidelines by amylase levels that were three times higher in the drainage fluid than the serum. POPFs were classified into three categories: (1) Grade A: Transient pancreatic fistula with no clinical impact; (2) grade B: Required a change in management or adjustment of the clinical course; and (3) grade C: Required a major change in clinical management or deviated from the normal clinical course[26]. Combined grade B + C fistulas were defined as “clinically relevant pancreatic fistula” (CR-POPF). DGE was defined as either nasogastric tube insertion after POD 3 or as the inability to tolerate solid food intake by POD 7. Chyle leakage was defined as a milky drain output or triglyceride levels of > 110 mg/dL in the drain fluid on any POD. Postoperative mortality was recorded as the 30-d mortality and in-hospital mortality.

Statistical analysis

Patient characteristics were compared by t-test, Wilcoxon Mann-Whitney test, χ2 test and Fisher’s exact test. A P-value of < 0.05 was considered statistically significant. Risk factors were analyzed by univariate and multivariate methods using binary logistic regression analysis. Independent risk factors were expressed as odds ratios (ORs) with 95%CI.

RESULTS
Patient characteristics and perioperative status

A total of 179 consecutive patients (95 males, 84 females) that underwent PD were included. One hundred and twenty-eight (71.5%) patients had classical PD and 51 (28.5%) patients had PPPD. Malignancy was diagnosed in 145 patients (79.9%) as follows: 62 ampullary carcinoma patients (44.8%), 40 pancreatic cancer patients (27.6%), 18 cholangiocarcinoma patients (12.4%) and 11 duodenal cancer patients (7.6%) (Table 1).

Table 1 Patient characteristics in postoperative pancreatic fistula and no postoperative pancreatic fistula groups.
Characteristic dataNo POPF (n = 91)POPF (n = 88)P-value95%CI
Age, mean (SD)60.7 (10.6)59.1 (11.2)0.3358.22-61.44
BMI, median (IQR)21.4 (20, 23.9)23.1 (20.8, 25.5)0.00522.05-23.22
Albumin, median (IQR)34.1 (31, 38.3)34.9 (32, 37.95)0.66733.38-35.10
Total bilirubin, median (IQR)4.1 (1.3, 13.2)1.3 (0.7, 5.6)0.0025.01-7.16
Pancreatic duct diameter (mm), median (IQR)3 (3, 5)3 (2, 5)0.0483.44-3.99
Operative time, median (IQR)420 (360, 540)480 (420, 570)0.014448.46-486.23
Blood loss (mL), median (IQR)1000 (600, 1500)800 (500, 1500)0.2361082-1459.66
LOH day, median (IQR)15 (12, 20)25 (17, 39.5)< 0.00123.14-32.87
Gender, n (%)
Male49 (53.8)46 (52.3)0.833
Female42 (46.2)42 (47.7)
DM, n (%)
No64 (70.3)69 (78.4)0.216
Yes27 (29.7)19 (21.6)
Hx of cardiovascular disease, n (%)
No82 (90.1)64 (72.7)0.003
Yes9 (9.9)24 (27.3)
PBD, n (%)
No36 (39.6)25 (28.4)0.116
Yes55 (60.4)63 (71.6)
Pancreatic texture, n (%)1
Hard/firm60 (68.2)27 (31.4)< 0.001
Soft28 (31.8)59 (68.6)
Type of resection, n (%)
PPPD20 (22.0)31 (35.2)0.05
Classical PD71 (78.0)57 (64.8)
Duct to mucosa vs Invagination
Duct to mucosa56 (61.5)63 (71.6)0.154
Invagination35 (38.5)25 (28.4)
Stent, n (%)
No73 (80.2)54 (61.4)0.005
Yes18 (19.8)34 (38.6)
External vs Internal, n (%)
External4 (22.2)12 (36.4)0.298
Internal14 (77.8)21 (63.6)
Malignant, n (%)
No18 (19.8)16 (18.2)0.785
Yes73 (80.2)72 (81.8)
Final diagnosis, n (%)
CA ampulla25 (27.5)37 (42.1)0.04
CA pancreas28 (27.5)12 (13.6)
CA duodenal8 (8.8)3 (3.4)
CA distal CBD7 (7.7)11 (12.5)
Other26 (28.5)25 (28.4)
Grading, n (%)
No91 (100)00
A058 (65.9)
B022 (25.0)
C08 (9.1)
Other complications
No86 (94.5)66 (75.0)< 0.001
Yes5 (5.5)22 (25.0)
30-d mortality, n (%)
No91 (100)85 (96.6)0.117
Yes03 (3.4)
Age, n (%)
< 7073 (80.2)73 (82.9)0.637
≥ 7018 (19.8)15 (17.1)
BMI, n (%)
< 2578 (85.7)63 (71.6)0.021
≥ 2513 (14.3)25 (28.4)
Albumin, n (%)
≥ 3075 (82.4)77 (87.5)0.342
< 3016 (17.6)11 (12.5)
Total bilirubin, n (%)
< 341 (45.1)56 (63.6)0.013
≥ 350 (54.9)32 (36.4)
Pancreatic duct diameter, n (%)
≥ 545 (49.4)23 (26.1)0.001
< 546 (50.6)65 (73.9)
Operative time, n (%)
< 42039 (42.9)21 (23.9)0.007
≥ 42052 (57.1)67 (76.1)
Blood loss, n (%)
< 100045 (49.5)54 (61.4)0.109
≥ 100046 (50.5)34 (38.6)
Patient characteristics and operative outcomes in patients with and without POPF

POPF were detected in 88 patients (49%). Fifty-eight patients (65.9%) had grade A POPF, 22 patients (25%) had grade B POPFs and eight patients (9.1%) had grade C POPFs. CR-POPF were detected in 30/179 patients (16.7%). The 30-d mortality rate was 1.67% (3/179). Table 1 compares the post-PD complications between POPF and no POPF groups. Age, serum albumin levels, operative blood loss, gender, diabetes mellitus and PBD were not statistically different between the two groups. However, statistically significant differences were observed in BMI, preoperative total serum bilirubin, pancreatic duct diameter, operative time, cardiovascular disease, pancreatic texture and trans-anastomotic stent between the two groups. The POPF group had a higher rate of other complications (5.5% vs 25%, P < 0.001) and a longer LOH (15 d vs 25 d, P < 0.001).

Risk factors for POPF

Univariate and multivariate analyses were used to identify risk factors for POPF (Table 2). Univariate analyses of the 88 patients with pancreatic fistula revealed the following risk factors for POPF: BMI > 25 (OR 2.38, 95%CI: 1.13-5.03, P = 0.005), pancreatic duct diameter (OR 2.765, 95%CI: 1.47-5.18, P = 0.002), operative time (OR 2.39, 95%CI: 1.26-4.55, P = 0.008), history of cardiovascular disease (OR 3.41, 95%CI: 1.48-7.86, P = 0.004), soft pancreatic texture (OR 4.682, 95%CI: 2.47-8.87, P < 0.001) and placement of a trans-anastomotic pancreatic duct stent (OR 2.55, 95%CI: 1.31-4.99, P = 0.006). Multivariate logistic regression analysis revealed soft pancreatic texture (OR 3.59, 95%CI: 3.01-17.35, P < 0.001) as the most significant risk factor for POPF.

Table 2 Univariate and multivariate logistic regression analysis of postoperative pancreatic fistula risk factors.
VariableUnivariate OR (95%CI)Univariate P-valueMultivariate OR (95%CI)Multivariate P-value
Age (yr)
< 70
≥ 700.833 (0.39-1.78)0.637
Body mass index (kg/cm2)
< 25
≥ 252.381 (1.13-5.03)0.0232.081 (0.86-5.03)0.104
Albumin
≥ 30
< 300.669 (0.29-1.54)0.344
Total bilirubin
< 3
≥ 30.468 (0.26-0.85)0.0131.455 (0.38-5.55)0.583
Pancreatic duct diameter
≥ 5 mm
< 5 mm2.765 (1.47-5.18)0.0023.148 (0.81-12.27)0.098
Operative time
< 420 min
≥ 420 min2.393 (1.26-4.55)0.0081.355 (0.59-3.07)0.465
Blood loss
< 1000
≥ 10000.616 (0.34-1.12)0.11
Gender
Male
Female1.065 (0.59-1.92)0.833
DM
No
Yes0.653 (0.33-1.29)0.218
Hx of cardiovascular disease
No
Yes3.417 (1.48-7.86)0.0042.612 (0.96-7.08)0.059
Preop biliary stent (no)
No
Yes1.649 (0.88-3.08)0.117
Pancreatic texture
Hard/firm
Soft4.682 (2.47-8.87)< 0.0013.598 (1.77-7.32)< 0.001
Type of resection
Pylorus-preserved pancreaticoduodenectomy
Pancreaticoduodenectomy0.518 (0.27-1.00)0.0510.807 (0.37-1.78)0.597
Duct to mucosa
Invagination0.635 (0.34-1.19)0.156
Stent (no)
No
Yes2.553 (1.31-4.99)0.0061.272 (0.52-3.09)0.595
External
Internal0.500 (0.13-1.87)0.303
Malignant (no)
No
Yes1.109 (0.52-2.34)0.785
Final diagnosis (CA ampulla)
CA pancreas0.324 (0.14-0.76)0.010.439 (0.16-1.19)0.105
CA duodenal0.253 (0.06-1.05)0.0580.533 (0.11-2.59)0.435
CA distal CBD1.062 (0.36-3.11)0.9131.188 (0.33-4.29)0.793
Other0.650 (0.31-1.37)0.2580.543 (0.22-1.35)0.189
Effect of POPF grade on patient characteristics and operative outcomes and predictive factors for CR-POPF

Preoperative total bilirubin and pancreatic reconstruction techniques (duct to mucosa vs invagination) were significantly different between grade A POPF and CR-POPF (Table 3). Univariate analysis revealed preoperative total serum bilirubin levels of more than 3 mg/dL as a potential risk factor for grade A POPF (OR 3.749, 95%CI: 1.48-9.51, P = 0.005). Multivariate analysis revealed total serum bilirubin levels of more than 3 mg/dL as the most significant predictive factor for CR-POPF (OR 4.50, 95%CI: 1.54-13.15, P = 0.006) (Table 4).

Table 3 Relationships between patient characteristics, operative outcome and postoperative pancreatic fistula grade.
Characteristic dataPOPF (grading)
P-value95%CI
A (n = 58)B + C (n = 30)
Age, mean (SD)59.2 (11.3)58.8 (11.4)0.87456.67-61.46
BMI, median (IQR)23.1 (20.4, 25.1)23.1 (21.1, 26.5)0.80522.62-24.45
Albumin, median (IQR)34.7 (32, 38)35.4 (32, 37.9)0.60333.38-35.58
Total bilirubin, median (IQR)0.9 (2, 5)3.3 (1.2, 12)0.013.44-6.66
Pancreatic duct diameter (mm), median (IQR)3 (2, 5)3 (2, 4)0.1753.07-3.79
Operative time, median (IQR)480 (420, 600)480 (360, 540)0.49462.22-511.75
Blood loss (mL), median (IQR)800 (500, 1500)900 (600, 1500)0.071985.10-1616.95
LOH day, median (IQR)21 (14, 30)42.5 (30, 60)< 0.00128.14-46.32
Gender, n (%)
Male34 (58.6)12 (40.0)0.097
Female24 (41.4)18 (60.0)
DM, n (%)
No45 (77.6)24 (80.0)0.794
Yes13 (22.4)6 (20.0)
Hx of cardiovascular disease, n (%)
No42 (72.4)22 (73.3)0.927
Yes16 (27.6)8 (26.7)
PBD, n (%)
No20 (34.5)5 (16.7)0.079
Yes38 (65.5)25 (83.3)
Pancreatic texture, n (%)
Hard/Firm20 (35.1)7 (24.1)0.301
Soft37 (64.9)22 (75.9)
Type of resection, n (%)
PPPD24 (41.4)7 (23.3)0.093
PD34 (58.6)23 (76.7)
Duct, n (%)
Duct to mucosa46 (79.3)17 (56.7)0.026
Invagination12 (20.7)13 (43.3)
Stent, n (%)
No32 (55.2)22 (73.3)0.097
Yes26 (44.8)8 (26.7)
External vs Internal, n (%)
External8 (32.0)4 (50.0)0.42
Internal14 (68.0)4 (50.0)
Malignant, n (%)
No12 (20.7)4 (13.3)0.396
Yes46 (79.3)26 (86.7)
Final diagnosis, n (%)
CA ampulla23 (39.6)14 (46.7)0.33
CA pancreas8 (13.8)4 (13.3)
CA duodenal3 (5.2)0
CA distal CBD5 (8.6)6 (20.0)
Other19 (32.8)6 (20.0)
Age, n (%)
< 7047 (81.0)26 (86.7)0.505
≥ 7011 (19.0)4 (13.3)
BMI, n (%)
< 2542 (71.4)21 (70.0)0.812
≥ 2516 (27.6)9 (30.0)
Albumin, n (%)
≥ 3050 (86.2)27 (90.0)0.743
< 308 (13.8)3 (10.0)
Total bilirubin, n (%)
< 343 (74.1)13 (43.3)0.004
≥ 315 (28.9)17 (56.7)
Pancreatic duct diameter, n (%)
≥ 512 (20.7)11 (36.7)0.106
< 546 (79.3)19 (63.3)
Operative time, n (%)
< 42012 (20.7)9 (30.0)0.331
≥ 42046 (79.3)21 (70.0)
Blood loss, n (%)
< 100037 (63.8)17 (56.7)0.515
≥ 100021 (36.2)13 (43.3)
Table 4 Univariate and multivariate logistic regression analysis of risk factors for clinically relevant-postoperative pancreatic fistula.
VariableUnivariate OR (95%CI)Univariate P-valueMultivariate OR (95%CI)Multivariate P-value
Age (yr)
< 70
≥ 700.657 (0.19-2.27)0.507
BMI (kg/cm2)
< 25
≥ 251.125 (0.43-2.96)0.812
Albumin
≥ 30
< 300.694 (0.17-2.84)0.611
Total bilirubin
< 3
≥ 33.749 (1.48-9.51)0.0054.506 (1.54-13.15)0.006
Pancreatic duct diameter (mm)
≥ 5
< 50.451 (0.17-1.20)0.11
Operative time (min)
< 420
≥ 4200.609 (0.22-1.66)0.334
Blood loss
< 1000
≥ 10001.347 (0.55-3.31)0.516
Gender
Male
Female2.125 (0.86-5.22)0.1
DM
No
Yes0.865 (0.29-2.56)0.794
Hx of cardiovascular disease
No
Yes0.954 (0.35-2.58)0.927
Preop biliary stent (no)
No
Yes2.631 (0.87-7.92)0.0852.24 (0.67-7.49)0.191
Pancreatic texture
Hard/firm
Soft
Type of resection
PPPD
PD2.319 (0.86-6.27)1.787 (0.54-5.92)0.342
Duct to mucosa
Invagination2.931 (1.12-7.67)0.0282.837 (0.89-9.08)0.079
Stent (no)
No
Yes0.447 (0.17-1.17)0.101
External
Internal0.471 (0.09-2.38)0.362
Malignant (no)
No
Yes1.695 (0.50-5.80)0.4
Final diagnosis (CA ampulla)
CA pancreas0.821 (0.21-3.24)0.779
CA duodenal----
CA distal CBD1.971 (0.51-7.68)0.328
Other0.519 (0.17-1.61)0.256
DISCUSSION

The most common perioperative complication of PD is POPF. POPF remains the leading cause of complications such as DGE and postoperative hemorrhage, which increase mortality[1-3] and the LOH. Many risk factors for POPF have been reported previously[4-9]. In the present study, the incidence of POPF and the 30-d mortality rate were similar to previous studies. In addition, we identified soft pancreatic texture as a main risk factor for POPF[8-12].

Our multivariate analysis showed that a soft pancreas is the most independent predictive factor for POPF. This is in agreement with previous studies[5,9-12,27]. There are many reasons why soft pancreatic tissue increases the risk of POPF. First, a soft pancreas makes it more difficult to secure PEA because friable pancreatic tissue cannot hold suture tension. As a result, suture materials cut through the pancreatic parenchyma and anastomosis fails. A soft pancreas is also prone to ischemia when manipulated, which disrupts anastomosis. Finally, a soft pancreas has enriched exocrine function and pancreatic enzymes are released when leakage occurs[9,11,27,28].

The assessment of pancreatic texture is controversial and subjective. Pancreatic texture is commonly assessed intraoperatively by palpation. Callery et al[11] reported the clinical risk score for POPF based on pancreatic texture, pancreatic duct diameter and intraoperative blood loss. They classified the pancreatic texture as firm or soft[11]. Some studies have classified pancreatic texture as hard, firm or soft, but the distinction between a hard and firm pancreas remains unclear[1,5].

Recently, Ansorge et al[29] reported similar risk factors for POPF. They classified the pancreatic texture into four grades, including very hard (severe chronic pancreatitis), hard (fibrotic or atrophic obstructed pancreatic gland), soft (unaffected compact gland), and very soft (unaffected fatty pancreas). They found that 44/100 patients had a hard pancreas. The rate of POPF in the very hard/hard groups was significantly different to that in the soft/very soft groups[29]. There is a newly developed tissue strain imaging technology reflecting tissue fibrosis or stiffness and is integrated into a conventional ultrasound system called acoustic radiation force impulse (ARFI). Lee et al[30] and Harada et al[30] reported the high accuracy of ARFI for prediction of the stiffness of pancreas preoperatively.

The relationship between soft and fatty pancreatic tissue has been well studied[28-29,32]. A fatty pancreas refers to the increasing infiltration of adipose tissue into the pancreas[28]. Ansorge et al[29] found that the softness of pancreatic tissue was strongly associated with fat levels in the tissue. This was supported by previous reports that a fatty pancreas is a risk factor for POPF[13,28,32]. Taken together, these findings suggest that the infiltration of adipose tissue into the pancreas is associated with soft pancreatic texture.

The assessment of pancreatic texture is difficult and subjective. Currently, there are no standard procedures for the intraoperative assessment of pancreatic texture. Pancreatic texture has commonly been assessed intraoperatively by palpation[5,11,29]. In the present study, we also assessed pancreatic texture by palpation. This subjective assessment of pancreatic texture could have differed from surgeon to surgeon.

Unfortunately, it was not possible to assess pancreatic texture during the preoperative evaluation. Tranchart et al[33] used computed tomography to predict the occurrence of severe pancreatic fistula following PD. They found that a visceral fat area of more than 84 cm3 was associated with a fatty pancreas (58.4% vs 48.1%, P = 0.005) and was a risk factor for CR-POPF (OR 8.16 95%CI: 2.2-3, P = 0.002). They suggested preoperative assessment of body fat distribution as a means of evaluating fat levels in the pancreas and predicting the occurrence of CR-POPF[33]. In our study, the incidence of CR-POPF is high when compared to previous studies[5,6,11,12]. This could be explained by the lower population of pancreatic cancer in this study that the pancreatic cancer is more likely to obstruct the pancreatic duct and therefore increase fibrosis of the pancreas[11].

Obstructive jaundice was previously regarded as the main factor increasing perioperative morbidity and mortality. The pathophysiology of obstructive jaundice includes increasing endotoxin concentrations in the portal circulation, altered Kupffer cell function affecting the reticuloendothelial system in the liver, over-activation of inflammatory cascades, decreased cellular immunity and renal dysfunction. These manifestations influence the nutritional status of patients. PBD decreased postoperative septic complications in mice by improving liver function, nutritional status, cell-mediated immune function, systemic endotoxemia, cytokine release and the overall immune response[34]. Regarding periampullary obstruction, endoscopic drainage approach today represents the procedure of choice with high succession rate[35,36].

In this study, a preoperative serum bilirubin level of more than 3 mg/dL was a risk factor for CR-POPF. Kimura et al[3] reported that serum bilirubin of more than 2.0 mg/dL was a significant preoperative risk factor for higher 30-d and in-hospital mortality rates following PD[3]. Gebauer et al[37] found that patients with POPF who underwent repeated surgery had higher in-hospital mortality (0.6 vs 0.7, P = 0.002) and total serum bilirubin levels (0.7 vs 1.1, P = 0.003) than POPF patients that did not undergo reoperation). In a previous study, multivariate binary logistic regression model analysis revealed that a serum bilirubin level of > 2.0 mg/dL is an independent risk factor for reoperation (OR 25.053, 95%CI: 3.486-180.069)[37]. Some previous studies have identified higher serum bilirubin levels in CR-POPF patients, but these differences were not statistically significant. For example, El Nakeeb et al[12] reported a preoperative bilirubin level of 4.6 mg/dL in patients with grade A POPF and 9.7 mg/dL in patients with CR-POPF, but this difference was not significant. This was supported by Braga et al[38], who detected higher total serum bilirubin in patients with grade III-IV complications than patients with grade 0-II complications (3.5 mg/dL vs 1.6 mg/dL). Again, this difference was not statistically significant. Fujii et al[39] found that endoscopic internal drainage posed a higher risk for POPF than endoscopic nasobiliary drainage.

In a recent systematic review, Scheufele et al[40] reported that POPF rates do not differ between PBD and no drainage groups. However, a higher infectious complications rate was detected in the PBD group. Most of the studies included in this review were retrospective studies, and the most frequent complications were wound-related[40]. A few randomized control trial studies have now been performed by a Dutch group. In these studies, the POPF rate did not differ between PBD and surgery first groups following PD. However, the population in the POPF group was only 16%, which may not have been high enough to obtain sufficient statistical power[31]. Current evidence does not recommend routine PBD because the rate of infectious (usually wound-related) complications is higher. However, a randomized control trial of a large population is needed to clarify this in the case of CR-POPF.

In this study, 66.8% of patients underwent PBD, which is higher than previous reports[39-41]. This could be explained by the fact that Thailand is a low to mid-income country, therefore patients with periampullary tumor and pancreatic cancer usually present with severe obstructive jaundice and have poor nutritional status. Serum bilirubin levels were higher than 15 mg/dL and serum albumin levels were less than 30 mg/dL in most patients. In addition, high-volume centers have patient congestion, limited resources and long waiting lists for operations.

This study was limited by the small study population. A larger population study might have revealed more significant risk factors of POPF.

In conclusion, we have identified a soft pancreas as an independent risk factor of POPF. A fatty pancreas is strongly associated with a soft pancreas and can be measured to predict CR-POPF. Preoperative detection of a fatty pancreas by CT and newly developed ultrasound technology is a potential method for predicting a soft pancreas preoperatively. However, this needs to be confirmed by large population studies. At the moment, PBD is not routinely recommended because the rate of infectious complications is higher. Further studies are required to clarify the link between preoperative obstructive jaundice and CR-POPF.

ARTICLE HIGHLIGHTS
Research background

Many risk factors have been reported for postoperative pancreatic fistula (POPF), including obesity, soft pancreatic texture, small pancreatic duct and low volume center. Some studies have investigated ways to improve the surgical outcome and reduce POPF, including the placement of an external and internal trans-anastomotic pancreatic duct, pancreatogastrostomy, omental roll-up around pancreaticoenteric (PE) anastomosis, application of fibrin sealants around PE anastomosis and prophylaxis with somatostatin analogs. However, the outcomes of these different methods remain controversial. Recently, a soft pancreas and high body mass index (BMI) were reported as the most common risk factors for POPF. However, POPF risk factors have not been studied in a Thai population before. The aim of this study was to analyze the risk factors of POPF following PD in a Thai tertiary care center.

Research motivation

The most common perioperative complication of pancreaticoduodenectomy is POPF. POPF remains the leading cause of complications such as DGE and postoperative hemorrhage, which increase mortality and the LOH. Many risk factors for POPF have been reported previously.

Research objectives

The aim of this study was to analyze the risk factors of POPF following PD in a Thai tertiary care center.

Research methods

The retrospective study design were required by reviewed data from January 2001 to December 2016, 210 consecutive patients underwent PD at the Department of Surgery in Ramathibodi Hospital, Bangkok, Thailand.

Research results

This is the study from tertiary care center from Thailand. To the best of the authors knowledge, this is the largest study from Thailand. The authors found that soft pancreatic tissue is the most significant risk factor for postoperative pancreatic fistula. A high preoperative serum bilirubin level (> 3 mg/dL) is the most significant risk factor for clinically relevant pancreatic fistula.

Research conclusions

The authors have identified a soft pancreas as an independent risk factor of POPF. A fatty pancreas is strongly associated with a soft pancreas and can be measured to predict CR-POPF. Preoperative detection of a fatty pancreas by CT is a potential method for predicting a soft pancreas preoperatively. Recently, the newly developed technology of ultrasonography have high accuracy to prediction of the stiffness of pancreas preoperatively. However, this needs to be confirmed by large population studies. At the moment, PBD is not routinely recommended because the rate of infectious complications is higher. Further studies are required to clarify the link between preoperative obstructive jaundice and CR-POPF.

Research perspectives

Preoperative detection of a fatty pancreas by CT and newly developed ultrasound technology is a potential method for predicting a soft pancreas preoperatively. which needs to be confirmed by large population studies. At the moment, PBD is not routinely recommended because the rate of infectious complications is higher. Further studies are required to clarify the link between preoperative obstructive jaundice and CR-POPF.

ACKNOWLEDGMENTS

The authors would thank Mr. Napaphat Poprom for reviewed the biostatistics.

Footnotes

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: Thailand

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

P- Reviewer: Chow WK, Gong JS, Smith RC S- Editor: Kong JX L- Editor: A E- Editor: Lu YJ

References
1.  McMillan MT, Vollmer CM Jr, Asbun HJ, Ball CG, Bassi C, Beane JD, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares K, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, Behrman SW. The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. J Gastrointest Surg. 2016;20:262-276.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 91]  [Cited by in F6Publishing: 94]  [Article Influence: 11.8]  [Reference Citation Analysis (0)]
2.  Hackert T, Hinz U, Pausch T, Fesenbeck I, Strobel O, Schneider L, Fritz S, Büchler MW. Postoperative pancreatic fistula: We need to redefine grades B and C. Surgery. 2016;159:872-877.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 76]  [Article Influence: 8.4]  [Reference Citation Analysis (0)]
3.  Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, Shimada M, Baba H, Tomita N, Nakagoe T. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014;259:773-780.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 268]  [Cited by in F6Publishing: 277]  [Article Influence: 27.7]  [Reference Citation Analysis (0)]
4.  Roberts KJ, Sutcliffe RP, Marudanayagam R, Hodson J, Isaac J, Muiesan P, Navarro A, Patel K, Jah A, Napetti S. Scoring System to Predict Pancreatic Fistula After Pancreaticoduodenectomy: A UK Multicenter Study. Ann Surg. 2015;261:1191-1197.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 92]  [Cited by in F6Publishing: 107]  [Article Influence: 13.4]  [Reference Citation Analysis (1)]
5.  Addeo P, Delpero JR, Paye F, Oussoultzoglou E, Fuchshuber PR, Sauvanet A, Sa Cunha A, Le Treut YP, Adham M, Mabrut JY, Chiche L, Bachellier P; French Surgical Association (AFC). Pancreatic fistula after a pancreaticoduodenectomy for ductal adenocarcinoma and its association with morbidity: a multicentre study of the French Surgical Association. HPB (Oxford). 2014;16:46-55.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 119]  [Article Influence: 11.9]  [Reference Citation Analysis (0)]
6.  Büchler MW, Friess H, Wagner M, Kulli C, Wagener V, Z’Graggen K. Pancreatic fistula after pancreatic head resection. Br J Surg. 2000;87:883-889.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 306]  [Cited by in F6Publishing: 323]  [Article Influence: 13.5]  [Reference Citation Analysis (0)]
7.  Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220:530-536.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 336]  [Cited by in F6Publishing: 384]  [Article Influence: 42.7]  [Reference Citation Analysis (0)]
8.  Frymerman AS, Schuld J, Ziehen P, Kollmar O, Justinger C, Merai M, Richter S, Schilling MK, Moussavian MR. Impact of postoperative pancreatic fistula on surgical outcome--the need for a classification-driven risk management. J Gastrointest Surg. 2010;14:711-718.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 41]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
9.  Hu BY, Wan T, Zhang WZ, Dong JH. Risk factors for postoperative pancreatic fistula: Analysis of 539 successive cases of pancreaticoduodenectomy. World J Gastroenterol. 2016;22:7797-7805.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 92]  [Cited by in F6Publishing: 89]  [Article Influence: 11.1]  [Reference Citation Analysis (0)]
10.  Fang CH, Chen QS, Yang J, Xiang F, Fang ZS, Zhu W. Body Mass Index and Stump Morphology Predict an Increased Incidence of Pancreatic Fistula After Pancreaticoduodenectomy. World J Surg. 2016;40:1467-1476.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 18]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
11.  Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216:1-14.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 653]  [Cited by in F6Publishing: 786]  [Article Influence: 65.5]  [Reference Citation Analysis (0)]
12.  El Nakeeb A, Salah T, Sultan A, El Hemaly M, Askr W, Ezzat H, Hamdy E, Atef E, El Hanafy E, El-Geidie A. Pancreatic anastomotic leakage after pancreaticoduodenectomy. Risk factors, clinical predictors, and management (single center experience). World J Surg. 2013;37:1405-1418.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 118]  [Cited by in F6Publishing: 127]  [Article Influence: 12.7]  [Reference Citation Analysis (0)]
13.  Gaujoux S, Cortes A, Couvelard A, Noullet S, Clavel L, Rebours V, Lévy P, Sauvanet A, Ruszniewski P, Belghiti J. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery. 2010;148:15-23.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 245]  [Cited by in F6Publishing: 264]  [Article Influence: 18.9]  [Reference Citation Analysis (0)]
14.  Akamatsu N, Sugawara Y, Komagome M, Shin N, Cho N, Ishida T, Ozawa F, Hashimoto D. Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. J Hepatobiliary Pancreat Sci. 2010;17:322-328.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 63]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
15.  Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. Ann Surg. 2014;260:244-251.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 306]  [Cited by in F6Publishing: 325]  [Article Influence: 36.1]  [Reference Citation Analysis (0)]
16.  Jang JY, Chang YR, Kim SW, Choi SH, Park SJ, Lee SE, Lim CS, Kang MJ, Lee H, Heo JS. Randomized multicentre trial comparing external and internal pancreatic stenting during pancreaticoduodenectomy. Br J Surg. 2016;103:668-675.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 48]  [Cited by in F6Publishing: 51]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
17.  Dong Z, Xu J, Wang Z, Petrov MS. Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev. 2016;CD008914.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 27]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
18.  Menahem B, Guittet L, Mulliri A, Alves A, Lubrano J. Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Ann Surg. 2015;261:882-887.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 96]  [Cited by in F6Publishing: 104]  [Article Influence: 11.6]  [Reference Citation Analysis (0)]
19.  Topal B, Fieuws S, Aerts R, Weerts J, Feryn T, Roeyen G, Bertrand C, Hubert C, Janssens M, Closset J; Belgian Section of Hepatobiliary and Pancreatic Surgery. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol. 2013;14:655-662.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 210]  [Cited by in F6Publishing: 222]  [Article Influence: 20.2]  [Reference Citation Analysis (0)]
20.  Xiong JJ, Tan CL, Szatmary P, Huang W, Ke NW, Hu WM, Nunes QM, Sutton R, Liu XB. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Br J Surg. 2014;101:1196-1208.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 100]  [Cited by in F6Publishing: 92]  [Article Influence: 9.2]  [Reference Citation Analysis (0)]
21.  Tian Y, Ma H, Peng Y, Li G, Yang H. Preventive effect of omental flap in pancreaticoduodenectomy against postoperative complications: a meta-analysis. Hepatogastroenterology. 2015;62:187-189.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Barakat O, Ozaki CF, Wood RP. Topically applied 2-octyl cyanoacrylate (Dermabond) for prevention of postoperative pancreatic fistula after pancreaticoduodenectomy. J Gastrointest Surg. 2012;16:1499-1507.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
23.  Cheng Y, Ye M, Xiong X, Peng S, Wu HM, Cheng N, Gong J. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. Cochrane Database Syst Rev. 2016;2:CD009621.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 18]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
24.  Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev. 2013;CD008370.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 64]  [Cited by in F6Publishing: 75]  [Article Influence: 6.8]  [Reference Citation Analysis (0)]
25.  Gans SL, van Westreenen HL, Kiewiet JJ, Rauws EA, Gouma DJ, Boermeester MA. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br J Surg. 2012;99:754-760.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 56]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
26.  Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8-13.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3282]  [Cited by in F6Publishing: 3388]  [Article Influence: 178.3]  [Reference Citation Analysis (0)]
27.  Lin JW, Cameron JL, Yeo CJ, Riall TS, Lillemoe KD. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg. 2004;8:951-959.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 282]  [Cited by in F6Publishing: 282]  [Article Influence: 14.1]  [Reference Citation Analysis (0)]
28.  Mathur A, Pitt HA, Marine M, Saxena R, Schmidt CM, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD. Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg. 2007;246:1058-1064.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 247]  [Cited by in F6Publishing: 264]  [Article Influence: 16.5]  [Reference Citation Analysis (0)]
29.  Ansorge C, Strömmer L, Andrén-Sandberg Å, Lundell L, Herrington MK, Segersvärd R. Structured intraoperative assessment of pancreatic gland characteristics in predicting complications after pancreaticoduodenectomy. Br J Surg. 2012;99:1076-1082.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 78]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
30.  Lee TK, Kang CM, Park MS, Choi SH, Chung YE, Choi JY, Kim MJ. Prediction of postoperative pancreatic fistulas after pancreatectomy: assessment with acoustic radiation force impulse elastography. J Ultrasound Med. 2014;33:781-786.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 20]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
31.  Harada N, Ishizawa T, Inoue Y, Aoki T, Sakamoto Y, Hasegawa K, Sugawara Y, Tanaka M, Fukayama M, Kokudo N. Acoustic radiation force impulse imaging of the pancreas for estimation of pathologic fibrosis and risk of postoperative pancreatic fistula. J Am Coll Surg. 2014;219:887-894.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 53]  [Cited by in F6Publishing: 53]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
32.  Rosso E, Casnedi S, Pessaux P, Oussoultzoglou E, Panaro F, Mahfud M, Jaeck D, Bachellier P. The role of “fatty pancreas” and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy. J Gastrointest Surg. 2009;13:1845-1851.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 104]  [Cited by in F6Publishing: 105]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
33.  Tranchart H, Gaujoux S, Rebours V, Vullierme MP, Dokmak S, Levy P, Couvelard A, Belghiti J, Sauvanet A. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy. Ann Surg. 2012;256:139-145.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 107]  [Cited by in F6Publishing: 112]  [Article Influence: 9.3]  [Reference Citation Analysis (0)]
34.  van der Gaag NA, Kloek JJ, de Castro SM, Busch OR, van Gulik TM, Gouma DJ. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. J Gastrointest Surg. 2009;13:814-820.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 121]  [Cited by in F6Publishing: 123]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
35.  Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg. 2013;257:191-204.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 123]  [Cited by in F6Publishing: 118]  [Article Influence: 10.7]  [Reference Citation Analysis (0)]
36.  Inamdar S, Slattery E, Bhalla R, Sejpal DV, Trindade AJ. Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort. JAMA Oncol. 2016;2:112-117.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 92]  [Article Influence: 11.5]  [Reference Citation Analysis (0)]
37.  Gebauer F, Kloth K, Tachezy M, Vashist YK, Cataldegirmen G, Izbicki JR, Bockhorn M. Options and limitations in applying the fistula classification by the International Study Group for Pancreatic Fistula. Ann Surg. 2012;256:130-138.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 46]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
38.  Braga M, Capretti G, Pecorelli N, Balzano G, Doglioni C, Ariotti R, Di Carlo V. A prognostic score to predict major complications after pancreaticoduodenectomy. Ann Surg. 2011;254:702-707; discussion 707-708.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 148]  [Cited by in F6Publishing: 160]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]
39.  Fujii T, Yamada S, Suenaga M, Kanda M, Takami H, Sugimoto H, Nomoto S, Nakao A, Kodera Y. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study. Pancreas. 2015;44:465-470.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 39]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
40.  Scheufele F, Schorn S, Demir IE, Sargut M, Tieftrunk E, Calavrezos L, Jäger C, Friess H, Ceyhan GO. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. Surgery. 2017;161:939-950.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 94]  [Cited by in F6Publishing: 103]  [Article Influence: 14.7]  [Reference Citation Analysis (0)]
41.  van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:129-137.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 717]  [Cited by in F6Publishing: 633]  [Article Influence: 45.2]  [Reference Citation Analysis (0)]